Phospho-EPOR (Y426) Antibody

說明書

中文名稱：

磷酸化-EPOR (Y426)兔多克隆抗體
貨號(hào)：

CSB-PA000757
規(guī)格：

￥1090
圖片：
Western Blot analysis of K562, cells using Phospho-EpoR (Y426) Polyclonal Antibody
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P19235
基因名：

EPOR
別名：

EPOR; Erythropoietin receptor; EPO-R
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Synthesized peptide derived from Human EpoR around the phosphorylation site of Y426.
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

WB, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
ELISA	1:20000

Protocols：

Western Blotting (WB) Protocol
ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.; Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
基因功能參考文獻(xiàn)：
1. Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), which identify a novel dimeric conformation for JAK2. PMID: 30044226
2. EpoR role in the proliferation and survival of non-small cell lung cancer cells PMID: 29345289
3. These results highlight the high intrinsic specificity of transmembrane domain interactions, demonstrate that a single methyl group can dictate specificity, and define the minimal chemical difference that can modulate the specificity of transmembrane domain interactions and the activity of transmembrane proteins. PMID: 28869036
4. Study reports for the first evidence that EPOR modulates breast cancer cell morphology changes upon tamoxifen treatment, which result in increased formation of cell protrusions and subsequent cell death and, proposes sustained AKT phosphorylation in EPOR-overexpressing cells as a mechanism that can lead to EPOR-induced tamoxifen resistance. PMID: 28714517
5. Authors retrospectively investigated whether TFR2 isoforms and EPOR are differentially expressed in MDS patients and whether the expression is associated with patients' clinical outcomes. PMID: 26914246
6. High EPOR expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma. PMID: 26919105
7. EPO-mediated EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro PMID: 27581518
8. this study shows that EPO could directly promote tumor progression via EPO receptor-expressing macrophages PMID: 27262376
9. No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA. CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT. PMID: 27640183
10. Overexpression of EPOR is associated with clear cell renal cell carcinoma. PMID: 27468719
11. HIF-1alpha and EPO-R may be an indicator of the aggressiveness of invasive breast cancers PMID: 27629849
12. These results identify EPOR as the secondbona fidehydroxylation-dependent substrate of VHL that potentially influences oxygen homeostasis and contributes to the complex genotype-phenotype correlation in VHL disease. PMID: 26846855
13. We report for a first time that functional EpoR is expressed in human rhabdomyosarcoma cell lines as well as by primary tumors from RMS patients. PMID: 26412593
14. erythrocyte lineage enforces exclusivity through upregulation of EKLF and its lineage-specific cytokine receptor (EpoR) while inhibiting both FLI-1 and the receptor TpoR (also known as MPL) for the opposing megakaryocyte lineage PMID: 26159733
15. A new point mutation in EPOR induces a short deletion in congenital erythrocytosis. PMID: 26010769
16. Data show that erythropoietin receptor antagonist EMP9 suppressed hemoglobin synthesis in xenografts of HeLa cells. PMID: 25874769
17. Data suggest that erythropoietin receptor (EPOR) could be a target to overcome therapeutic resistance toward ionizing radiation or temozolomide. PMID: 25544764
18. transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles PMID: 25418301
19. while EPO can stimulate NO production, NO in turn can regulate EPOR expression in endothelial cells during hypoxia PMID: 24518819
20. In HBV-related HCC, the levels of EpoR mRNA and protein in non-tumour cirrhotic livers were positively correlated with tumour cell differentiation, which is a favourable predictor of disease-specific survival. PMID: 23496059
21. This study reveals high EPOR level as a potential novel positive prognostic marker in human lung lung adenocarcinoma. PMID: 24155958
22. 3 novel EPOR mutations in primary familial and congenital polycythemia--Del1377-1411, a C1370A and G1445--were chimerized with EGFR to study signalling and metabolism of the chimeric receptors. PMID: 24533580
23. Data show that erythropoietin receptor (EPOR) protein is expressed in breast cancer cells, where it appears to promote proliferation by an EPO-independent mechanism in estrogen receptor alpha (ERalpha) expressing breast cancer cells. PMID: 24502950
24. Epo-R is expressed in bone marrow-derived macrophages from multiple myeloma and monoclonal gammopathy of undetermined significance patients. The Epo/Epo-R pathway may be involved in the regulation of angiogenic response occurring in MM. PMID: 23881169
25. Data suggest that adipose tissue-specific disruption of EPO receptor does not alter adipose tissue expansion, adipocyte morphology, insulin resistance, inflammation, or angiogenesis. PMID: 23885016
26. Sp1 may significantly affect the number of EPO-R molecules present on the surface of activated CD4(+) lymphocytes PMID: 23577103
27. EPOR expression may be involved in tumor progression and proliferation in HER2-positive breast cancer.EPOR contributes to the mechanism of trastuzumab resistance in breast cancer. PMID: 23117856
28. TAL1 binds to the EPO-R promoter to activate EPO-R expression PMID: 22982397
29. High EPOR expression in OSCC is associated with an aggressive tumor behavior and poorer prognosis in the univariate analysis among patients with OSCC. PMID: 22639817
30. Erythropoietin is capable of downregulating erythropoietin receptor when it acts early within HepG2 cells. PMID: 22227182
31. the biology of the EpoR in ovarian cancer cells PMID: 22552716
32. The absence of functional Epo receptor activity in human skeletal muscle indicates that the long-term effects are indirect and probably related to an increased oxidative capacity in this tissue PMID: 22384088
33. a critical role for membrane raft in recruitment and assembly of Epo-R and signal intermediates into discrete membrane signaling units PMID: 22509308
34. New knowledge concerning regulated EPOR expression and trafficking therefore is provided, together with new insight into mechanisms via which mutated EPOR-T polycythemia alleles dysregulate the erythron. PMID: 22253704
35. These data support that EpoR is functional in melanoma and EpoR activation may promote melanoma progression, and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo. PMID: 21860424
36. The expression of EPOR and TPOR on CD34+ CD59+ bone marrow cells are significantly higher than those on CD34+ CD59- cells of paroxysmal nocturnal hemoglobinuria patients. PMID: 22338178
37. STAT5 phosphorylation levels of EPO and TPO receptors are elevated in bone marrow cells of patients with paroxysmal nocturnal hemoglobinuria. PMID: 22093990
38. ETV6-RUNX1 directly activates ectopic expression of a functional EPOR and provides cell survival signals that may contribute critically to persistence of covert premalignant clones in children. PMID: 21900195
39. EPOR signalling in tumour cells is involved in the control of glioma growth. PMID: 21749867
40. EPO-R cytosolic lysine residues enhance receptor function, most probably through ubiquitination and/or other post-translational modifications. PMID: 21291419
41. The Epo/EpoR complex plays a critical role in the adhesion and migration of rat fibroblasts, and its functional inactivation is associated with PLC-gammal-dependent reduction of cell-matrix adhesion and this also affects cell migration. PMID: 21360263
42. Detected is a novel heterozygous frameshift mutation in exon 8 of the EPOR resulting in primary familial and congenital polycythaemia. PMID: 21437635
43. EPOR is expressed in cells of acute leukemia, but the expression level in low. The EPOR expression rate shows no significant difference between AML and ALL. PMID: 19099624
44. High EpoR is associated with angiogenesis in glioma. PMID: 20614229
45. Tumor vessels exhibited EpoR, pJAK-2, and pSTAT-5 immunoreactivity PMID: 20336349
46. results suggest that spermatozoa express EPO receptor on plasma membrane, which might act to protect these cells from damage after ejaculation. PMID: 20884294
47. EpoR signaling is absolutely required for Parvovirus B19 replication in ex vivo-expanded erythroid progenitor cells after initial virus entry and at least partly accounts for the remarkable tropism of B19V infection for human erythroid progenitors. PMID: 20861249
48. a regulatory role of EPO/EPOR pathway in human circulating endothelial precursors homeostasis PMID: 20700488
49. Data show that sEpoR is detectable as a 27kDa protein in the serum of dialysis patients, and that higher serum sEpoR levels correlate with increased erythropoietin requirements. PMID: 20169072
50. EpoR mRNA was detected in essentially all cell types examined, including primary endothelial, renal, cardiac, and neuronal cells but 10- to 100-fold lower than Epo-responsive cells PMID: 20124513
顯示更多

收起更多
相關(guān)疾病：

Erythrocytosis, familial, 1 (ECYT1)
亞細(xì)胞定位：

Cell membrane; Single-pass type I membrane protein.; [Isoform EPOR-S]: Secreted. Note=Secreted and located to the cell surface.
蛋白家族：

Type I cytokine receptor family, Type 1 subfamily
組織特異性：

Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors. Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EP
數(shù)據(jù)庫(kù)鏈接：

HGNC: 3416

OMIM: 133100

KEGG: hsa:2057

STRING: 9606.ENSP00000222139

UniGene: Hs.631624

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human